Brief: Mira Pharmaceuticals succesfully develops topical version of its therapy for localized neuropathic and inflammatory pain
13/03/2025 12:06
March 13 (Reuters) - Mira Pharmaceuticals Inc MIRA.O: MIRA PHARMACEUTICALS INC - ANNOUNCES SUCCESSFUL FORMULATION OF KETAMIR-2 TOPICAL TREATMENT MIRA PHARMACEUTICALS INC - ADVANCING KETAMIR-2 TOPICAL TREATMENT DEVELOPMENT FOR FUTURE CLINICAL TRIALS Further company coverage: MIRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing